HondaK., NittaK., HoritaS., YumuraW., NiheiH.Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure.Nephron1996; 72: 171–6.
2.
MateijsenM.A., van der WalA.C., HendriksP.M., ZweersM.M., MulderJ., StruijkD.G.Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis.Perit Dial Int1999; 19: 517–25.
3.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
4.
WieslanderA.P., KjellstrandP.T., RippeB.Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations.Perit Dial Int1995; 15(Suppl 7): S52–9.
5.
LindenT., CohenA., DeppischR., KjellstrandP., WieslanderA.3,4-Dideoxyglucosone-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis.Kidney Int2002; 62: 697–703.
6.
Nilsson-ThorellC.B., MuscaluN., AndrenA.H., KjellstrandP.T., WieslanderA.P.Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes.Perit Dial Int1993; 13: 208–13.
7.
LindenT., ForsbackG., DeppischR., HenleT., WieslanderA.3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis.Perit Dial Int1998; 18: 290–3.
8.
KjellstrandP., ErixonM., WieslanderA., LindenT., MartinsonE.Temperature: the single most important factor for degradation of glucose fluids during storage.Perit Dial Int2004; 24: 385–91.
9.
ErixonM., LindenT., KjellstrandP., CarlssonO., ErnebrantM., GunitaF.PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization.Perit Dial Int2004; 24: 392–8.
10.
WieslanderA.P., NordinM.K., MartinsonE., KjellstrandP.T., BobergU.C.Heat-sterilized PD fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes.Clin Nephrol1993; 39: 343–8.
11.
HendersonI.S., CouperI.A., LumsdenA.Potentially irritant glucose metabolites in unused CAPD fluid. In: MaherJ.F., WinchesterJ.F., eds. Frontiers in Peritoneal Dialysis.New York: Field, Rich and Associates; 1986: 261–4.
12.
WieslanderA.P., NordinM.K., KjellstrandP.T., BobergU.C.Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929.Kidney Int1991; 40: 77–9.
13.
WieslanderA., AndrenA.H., Nilsson ThorellC.B., MuscaluN., KjellstrandP.T., RippeB.Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro?Perit Dial Int1995; 15: 348–52.
14.
WitowskiJ., KorybalskaK., WisniewskaJ., BreborowiczA., GahlG.M., FreiU.Effects of glucose degradation products on human peritoneal mesothelial cell function.J Am Soc Nephrol2000; 11: 729–39.
LeungJ.C.K., ChanL.Y.Y., LiF.K., TangS.C.W., ChanK.W., ChanT.M.Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF.Nephrol Dial Transplant2005; 20: 1336–49.
17.
WitowskiJ., WisniewskaJ., KorybalskaK., BenderT.O., BreborowiczA., GahlG.M.Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells.J Am Soc Nephrol2001; 12: 2434–41.
18.
JonassonP., BraideM.Acute in vivo toxicity of heat-sterilized glucose peritoneal dialysis fluids to rat peritoneal macrophages.Perit Dial Int1998; 18: 376–81.
19.
ParkS.H., LeeE.G., KimI.S., KimY.J., ChoD.K., KimY.L.Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.Perit Dial Int2004; 24: 115–22.
20.
MortierS., FaictD., LameireN.H., De VrieseA.S.Benefits of switching from a conventional to a low-GDP bicarbonate/ lactate-buffered dialysis solution in a rat model.Kidney Int2005; 67: 1559–65.
21.
HiraharaI., KusanoE., YanagibaS., MiyataY., AndoY., MutoS.Peritoneal injury by methylglyoxal in peritoneal dialysis.Perit Dial Int2006; 26: 380–92.
22.
OkabeE., TomoT., TezonoK., KikuchiH., KadotaJ., NasuM.Synergistic cytotoxicity of acidity and glucose degradation products in peritoneal dialysis fluid.J Artif Organs2004; 7: 155–60.
BerlangaJ., CibrianD., GuillenI., FreyreF., AlbaJ., Lopez-SauraP.Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds.Clin Sci2005; 109: 83–95.
26.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis with low ultra-filtration.Nephrol Dial Transplant1999; 14: 1541–9.
27.
InagiR., MiyataT., YamamotoT., SuzukiD., UrakamiK., SaitoA.Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis.FEBS Lett1999; 463: 260–4.
28.
MiyataT., HorieK., UedaY., FujitaY., IzuharaY., HiranoH.Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.Kidney Int2000; 58: 425–35.
29.
LapollaA., FlaminiR., LupoA., AricoN.C., RugiuC., ReitanoR.Evaluation of glycol and methylglyoxal levels in uremic patients under peritoneal dialysis.Ann N Y Acad Sci2005; 1043: 217–24.
30.
MortierS., LameireN.H., De VrieseA.S.Animal models in peritoneal dialysis research: a need for consensus.Perit Dial Int2005; 25: 16–24.
31.
BreborowiczA., KnapowskiJ.Augmentation of peritoneal dialysis clearance with procaine.Kidney Int1984; 26: 392–6.
32.
TranL., RodelaH., HayJ.B., OreopoulosD., JohnstonM.G.Quantitation of lymphatic drainage of the peritoneal cavity in sheep: comparison of direct cannulation techniques with indirect methods to estimate lymph flow.Perit Dial Int1993; 13: 270–9.
33.
ZareieM., de VrieseA.S., HekkingL.H., ter WeeP.M., SchalkwijkC.G., DriesprongB.A.Immunopathological changes in a uraemic rat model for peritoneal dialysis.Nephrol Dial Transplant2005; 20: 1350–61.
34.
HolmesC.J., ShockleyT.R.Strategies to reduce glucose exposure in peritoneal dialysis patients.Perit Dial Int2000; 20(Suppl 2): S37–41.
35.
Le PooleC.Y., van IttersumF.J., WeijmerM.C., ValentijnR.M., ter WeeP.M.Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study.Adv Perit Dial2004; 20: 170–6.
36.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
37.
LeeH.Y., ParkH.C., SeoB.J., DoJ.Y., YungS.R., HyunY.S.Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).Perit Dial Int2005; 25: 248–55.
